Ginkgo Bioworks today announced it expanded its strategic partnership with Novo Nordisk to manufacture medicines for chronic diseases. Under the framework agreement, the partnership is slated to run over five years. Ginkgo Bioworks develops a platform for cell programming and biosecurity, while Novo Nordisk develops a series of medications for chronic conditions, including its Wegovy…